A phase II, proof of concept study to evaluate the safety and efficacy of Trabodenoson in patients with optic neuropathies and degenerative retinal diseases.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Trabodenoson (Primary)
- Indications Optic nerve disorders; Retinal degeneration
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 31 Mar 2015 Inotek Pharmaceuticals expects to initiate this study in the second half of 2015, according to the company SEC filing report 10-K 2014.
- 31 Mar 2015 New trial record